Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Autor:
Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, Brett M. Stevens
Publikováno v:
Blood Advances
Key Points Patients with AML who received IC were compared with those who received ven to investigate predictors of outcomes.Presence of RUNX1 mutations is associated with better outcomes for ven/aza compared with IC.
Visual Abstract
Veneto
Visual Abstract
Veneto
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Johan Maertens, Annoek E.C. Broers, Yvette van Norden, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Michel van Gelder, Jan J. Cornelissen, Wendelien Zeijlemaker, Burak Kalin, Ellen Meijer, Dimitri Breems, Eric Braakman, Tim Grob
Publikováno v:
BLOOD ADVANCES, 4(18), 4430-4437. American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of e
Autor:
Oludamilola Olajide, Allison M. Deal, Nilanjan Ghosh, Jeanne F. Noe, Stephen M. Ansell, Thomas C. Shea, Nishitha Reddy, Steven I. Park, Lihua E. Budde
Publikováno v:
Blood Adv
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Jacqueline C. Barrientos, Susan O'Brien, Ulrich Jaeger, Nishitha Reddy, Jennifer R. Brown, Steven Coutre, Constantine S. Tam, Peter Hillmen, Danelle F. James, John C. Byrd, Richard R. Furman, John M. Pagel, Patrick Thornton, Remus Vezan, Paul M. Barr, Jan A. Burger, Sandra Dai, Jennifer A. Woyach, Carol Moreno, Thomas J. Kipps, Stephen P. Mulligan, Marco Montillo
Publikováno v:
Blood
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relaps
Autor:
Maro Ohanian, Alessandra Ferrajoli, Mariela Sivina, Fong Clow, Zeev Estrov, Graciela M. Nogueras-Gonzalez, Michael J. Keating, Thomas Mathew, Ekaterina Kim, Xuelin Huang, Jeffrey L. Jorgensen, William G. Wierda, Hagop M. Kantarjian, Philip A. Thompson, Nitin Jain, Jianling Li, Tapan M. Kadia, Jan A. Burger, Michael Andreeff, Mei Cheng, Susan O'Brien
Publikováno v:
Blood. 133:1011-1019
Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-ce
Publikováno v:
Blood. 132:2722-2729
Blastoid mantle cell lymphoma is characterized by highly aggressive features and a dismal clinical course. These blastoid and pleomorphic variants are defined by cytomorphological features, but the criteria are somewhat subjective. The diagnosis may
Autor:
David M. Aboulafia, Erin Reid, Juan Carlos Ramos, Frank Maldarelli, Ronald T. Mitsuyasu, David Looney, Ethel Cesarman, Jeannette Y. Lee, Sara Yahyaei, Ariela Noy, Richard F. Ambinder, David H. Henry, Joseph A. Sparano, William Wachsman
Publikováno v:
Blood Advances. 2:3618-3626
HIV-associated lymphomas (HALs) have high rates of latent infection by gammaherpesviruses (GHVs). We hypothesized that proteasome inhibition would induce lytic activation of GHVs and inhibit HIV infectivity via preservation of cytidine deaminase APOB
Autor:
Eric Seifter, Sergio Giralt
Publikováno v:
Hematology. 2018:103-109
With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has